Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer
- 12 June 2013
- journal article
- phase i-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 32 (2) , 279-286
Abstract
Background Preclinical data have shown that lenalidomide and sorafenib target endothelial cells, inhibiting growth of ocular melanoma cells in a xenograft model. We conducted a Phase I study of lenalidomide and sorafenib in patients with advanced cancer. Methods During the escalation phase, lenalidomide (days 1–21) and sorafenib (days 1–28) were given orally once daily at the following respective doses: level 1 (10 mg, 200 mg); level 2 (10 mg, 400 mg); level 3 (20 mg, 400 mg); and level 4 (25 mg, 400 mg) (1 cycle = 28 days). A “3 + 3” study design was used. Results Forty-one patients were treated (median age: 50 years). The most common diagnoses were adenoid cystic carcinoma (N = 9), ovarian adenocarcinoma (N = 7), and melanoma (N = 6); 142 cycles (median: 3) were administered. No dose-limiting toxicities were noted. The maximum tested dose (dose level 4) was used in the expansion phase. Grade 3–4 treatment-related toxicities were neutropenia, thrombocytopenia, skin rash, and thromboembolism. Of 38 patients who were evaluable for response, stable disease (SD) was noted in 53 % of patients (SD ≥6 months: 16 %). Tumor types with SD ≥ 6 months were as follows: ocular melanoma, 2/2 (100 %); other melanoma, 1/4 (25 %); adenoid cystic carcinoma, 2/9 (22 %); and ovarian cancer, 1/6 (17 %). The median progression-free survival duration was 3.5 months (95 % CI, 1.9–5.0), and the median overall survival duration was 12.3 months (95 % CI, 10.1–14.5). Conclusions Lenalidomide and sorafenib was well tolerated and associated with disease stabilization for ≥6 months in patients with melanoma, adenoid cystic carcinoma, and ovarian adenocarcinoma.Keywords
This publication has 23 references indexed in Scilit:
- A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue CorrelatesPLOS ONE, 2010
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialBritish Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaJournal of Translational Medicine, 2007
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsThe Oncologist, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase II study of lenalidomide in patients with metastatic renal cell carcinomaCancer, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignanciesEuropean Journal of Cancer, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000